Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients

[1]  Philip D. Harvey,et al.  Twenty‐year progression of body mass index in a county‐wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis , 2017, Bipolar disorders.

[2]  J. McGrath,et al.  Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. , 2017, The lancet. Psychiatry.

[3]  D. Siskind,et al.  Metabolic monitoring and management among clozapine users , 2017, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

[4]  C. Hewitt,et al.  The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis , 2017, PloS one.

[5]  D. Vancampfort,et al.  How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression , 2016, Schizophrenia Research.

[6]  V. Carr,et al.  Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis , 2016, Epidemiology and Psychiatric Sciences.

[7]  J. Leung,et al.  Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis , 2016, PloS one.

[8]  A. Watkins,et al.  Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic‐induced weight gain in first‐episode psychosis , 2016, Early intervention in psychiatry.

[9]  B. Stubbs,et al.  How sedentary are people with psychosis? A systematic review and meta-analysis , 2016, Schizophrenia Research.

[10]  Denise Juliano-Bult,et al.  Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review. , 2015, Schizophrenia bulletin.

[11]  D. Vancampfort,et al.  Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis , 2015, World psychiatry : official journal of the World Psychiatric Association.

[12]  Robert M McCarron,et al.  Clinical management of comorbid diabetes and psychotic disorders. , 2015, The lancet. Psychiatry.

[13]  M. Srisurapanont,et al.  Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. , 2015, Journal of psychiatric research.

[14]  A. Mackinnon,et al.  Cardiometabolic Risk Indicators That Distinguish Adults with Psychosis from the General Population, by Age and Gender , 2013, PloS one.

[15]  F. Dickerson,et al.  A behavioral weight-loss intervention in persons with serious mental illness. , 2013, The New England journal of medicine.

[16]  D. Vancampfort,et al.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. , 2013, Schizophrenia bulletin.

[17]  P. McGuire,et al.  The dietary pattern of patients with schizophrenia: a systematic review. , 2013, Journal of psychiatric research.

[18]  A. Mackinnon,et al.  Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis , 2012, The Australian and New Zealand journal of psychiatry.

[19]  V. Steen,et al.  Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. , 2012, The international journal of neuropsychopharmacology.

[20]  Marc De Hert,et al.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs , 2012, Nature Reviews Endocrinology.

[21]  S. Gee,et al.  Augmentation of clozapine with a second antipsychotic – a meta‐analysis , 2012, Acta psychiatrica Scandinavica.

[22]  B. Druss,et al.  Understanding Excess Mortality in Persons With Mental Illness: 17-Year Follow Up of a Nationally Representative US Survey , 2011, Medical care.

[23]  Ya-Mei Bai,et al.  Association of weight gain and metabolic syndrome in patient taking Clozapine: a 8-year cohort study , 2010, Annals of General Psychiatry.

[24]  G. Liguori,et al.  Persistent Increase of Prevalence of Metabolic Syndrome Among U.S. Adults: NHANES III to NHANES 1999–2006 , 2010, Diabetes Care.

[25]  E. Skinner,et al.  Pattern of mortality in a sample of Maryland residents with severe mental illness , 2010, Psychiatry Research.

[26]  D. Goff,et al.  Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. , 2010, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[27]  H. Inskip,et al.  Twenty-five year mortality of a community cohort with schizophrenia , 2010, British Journal of Psychiatry.

[28]  Beverley Balkau,et al.  AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures , 2010, The Medical journal of Australia.

[29]  G. Fairbrother,et al.  Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. , 2009, Archives of psychiatric nursing.

[30]  A. Cipriani,et al.  Does the addition of a second antipsychotic drug improve clozapine treatment? , 2009, Schizophrenia bulletin.

[31]  J. Lieberman,et al.  Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study , 2008, Schizophrenia Research.

[32]  S. Saha,et al.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? , 2007, Archives of general psychiatry.

[33]  Jeff J Guo,et al.  Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. , 2006, The Journal of clinical psychiatry.

[34]  J. Shaw,et al.  Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[35]  Craig W. Colton,et al.  Congruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States , 2006, Preventing chronic disease.

[36]  G. Remington,et al.  Validation of a physical activity assessment tool for individuals with schizophrenia , 2006, Schizophrenia Research.

[37]  E. Hamera,et al.  A psychiatric rehabilitation approach to weight loss. , 2006, Psychiatric rehabilitation journal.

[38]  J. Lieberman,et al.  Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III , 2005, Schizophrenia Research.

[39]  F. Dickerson,et al.  Physical Activity Patterns in Adults With Severe Mental Illness , 2005, The Journal of nervous and mental disease.

[40]  D. Goff,et al.  Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. , 2005, The Journal of clinical psychiatry.

[41]  X. Tu,et al.  Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. , 2005, The Journal of clinical psychiatry.

[42]  R. Rosenheck,et al.  Clinicians' reasons for antipsychotic coprescribing. , 2004, The Journal of clinical psychiatry.

[43]  D. Jeste,et al.  Atypical antipsychotics and glucose dysregulation: a systematic review , 2004, Schizophrenia Research.

[44]  C. Koro,et al.  The effects of antipsychotic therapy on serum lipids: a comprehensive review , 2004, Schizophrenia Research.

[45]  R. McCreadie,et al.  Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. , 2003, The British journal of psychiatry : the journal of mental science.

[46]  D. Ford,et al.  Prevalence and Correlates of Obesity in a Community Sample of Individuals with Severe and Persistent Mental Illness , 2003, The Journal of nervous and mental disease.

[47]  B. Ainsworth,et al.  International physical activity questionnaire: 12-country reliability and validity. , 2003, Medicine and science in sports and exercise.

[48]  R. Ganguli,et al.  Nutritional assessment of patients with schizophrenia: a preliminary study. , 2003, Schizophrenia bulletin.

[49]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[50]  P. Sparén,et al.  Mortality and causes of death in schizophrenia in Stockholm County, Sweden , 2000, Schizophrenia Research.

[51]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[52]  D. Goff,et al.  Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. , 2000, The American journal of psychiatry.

[53]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[54]  J. Kane,et al.  Clozapine and weight gain. , 1994, The Journal of clinical psychiatry.

[55]  C. Pomerleau,et al.  Reliability of the Fagerstrom Tolerance Questionnaire and the Fagerstrom Test for Nicotine Dependence. , 1994, Addictive behaviors.

[56]  J. Lohr,et al.  Smoking and schizophrenia , 1992, Schizophrenia Research.

[57]  D. Goff,et al.  Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. , 1992, The American journal of psychiatry.

[58]  J. Lamberti,et al.  Weight gain among schizophrenic patients treated with clozapine. , 1992, The American journal of psychiatry.

[59]  R. Bland,et al.  Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study* , 1991, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[60]  K. Fagerström,et al.  Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. , 1978, Addictive behaviors.